Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira

NEW YORK, July 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Mylan Inc. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS) and Hospira, Inc. (NYSE: HSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4724-100free.

--
Actavis plc Analyst Notes
On July 8, 2014, Actavis plc (Actavis) announced that it has filed an Abbreviated New Drug Application (ANDA) with the FDA for the approval to market Dalfampridine Extended-release Tablets, 10mg, which is a generic version of Acorda Therapeutics' Ampyra - a treatment to improve walking in patients with multiple sclerosis. As a result, Acorda Therapeutics filed suit against the Company on July 7, 2014 seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain US Patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA until July 22, 2017. According to the Company, the available information makes it believe that it may be a first applicant to file an ANDA for the generic version of Ampyra and, following ANDA approval, may be entitled to 180 days of generic market exclusivity. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/ACT/report.pdf

--
Salix Pharmaceuticals, Ltd. Analyst Notes
On July 8, 2014, Salix Pharmaceuticals, Ltd. (Salix) announced a definitive merger agreement with Cosmo Pharmaceuticals S.p.A. (Cosmo), under which Salix will combine with Cosmo's subsidiary Cosmo Technologies Limited (Cosmo Tech). Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Cosmo Tech, and will change its name to Salix Pharmaceuticals, plc, which is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market. Further, Salix expects the transaction to be modestly accretive to its EPS in 2016 and increasingly accretive thereafter. The full analyst notes on Salix are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/SLXP/report.pdf

--
Mylan Inc. Analyst Notes
On July 8, 2014, Mylan Inc. (Mylan) announced the launch of Telmisartan Tablets USP, 20mg, 40mg, and 80mg, the generic version of Boehringer Ingelhem's Micardis Tablets. Mylan informed that it has received final approval from the FDA for its ANDA for Micardis, which is indicated for the treatment of hypertension, to lower blood pressure. The full analyst notes on Mylan are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/MYL/report.pdf

--
Zoetis Inc. Analyst Notes
On June 30, 2014, Zoetis Inc. (Zoetis) announced that intends host a webcast and conference call on its Q2 2014 financial results on August 5, 2014, at 8:30 a.m. EDT. The call will be hosted by Zoetis CEO, Juan Ramon Alaix, and Senior Vice President of Operations and Acting CFO, Glenn David, who will together review the results and respond to analysts' questions. The full analyst notes on Zoetis are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/ZTS/report.pdf

--
Hospira, Inc. Analyst Notes
On July 4, 2014, Hospira, Inc. (Hospira) announced that it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility, located in Aurangabad, India, and an associated R&D facility, based in Chennai, India, from Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) in a transaction valued at approximately $218 million, after settling prior advances of approximately $30 million. "Hospira's acquisition of the Orchid API facility will support supply continuity of key beta-lactam antibiotic products, improve our cost position and pave the way for future API development," said Dr. C. Bhaktavatsala Rao, President and Managing Director of Hospira India. The Company further noted that the transaction between Hospira and Orchid, originally announced in August 2012, has received all necessary regulatory and legal approvals. The full analyst notes on Hospira are available to download free of charge at:

http://www.analystsreview.com/Jul-14-2014/HSP/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED